hard to comment on the overall market, but I expect another trial will be needed to satisfy the FDA and I have factored this in. so I don't see a trial announcement causing share price decline, if anything it just provides clarity to what most expect. A surprise approval of course would be nice.
vivagel is starting to be distributed globally (ex US) and in the coming quarters we should start to see an increase in recurring revenue. I see this as important and something we should be watching closely in 2020. they have produced 100,000 units so far, let's see that monetized and increasing as more markets open up. But most importantly, it is 'planned' that AZD0466 will enter the clinic before year end and the Dep Doc phase II trial will conclude in first half of 2020 CY. At this stage of the company's development i think most holders now place greater importance on the Dep milestones than vivagel & FDA approval, although still relevant of course.
SPL Price at posting:
$1.33 Sentiment: Buy Disclosure: Held
